Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Semaglutide

STEP HFpEF DM

Novo Nordisk · Phase 3 · Completed · Enrollment 617

NCT04916470

EudraCT 2020-004170-22

ArmNauseaVomitingDiarrheaDiscontinuationDeaths
Semaglutide 2.4 mg once weekly (OW)55 participants26 participants42 participantsn/r6
Semaglutide placebo OW18 participants7 participants20 participantsn/r10

A count stays a count. This page does not turn a count into a percent.